On Sept 26, Bayer launched its global life sciences co-creation platform — Bayer Co.Lab China — in the Pudong New Area. This initiative aims to enhance the technological innovation capabilities of local enterprises in cutting-edge fields such as cell and gene therapy, thereby empowering domestic innovation.

Announced and signed at the sixth China International Import Expo on Nov 7 last year, the quick establishment of Bayer Co.Lab China in less than a year underscores Bayer's commitment to the Chinese market and its recognition of Pudong's innovative environment.

Located in Shanghai's Pudong, which boasts resources from top universities and leading research institutions, Bayer Co.Lab China will focus on forefront innovation areas including cell and gene therapies, oncology, and new technology platforms.

The platform will leverage Bayer's global R&D network and expertise to help biotech startups connect with international innovation collaboration networks, providing resources and a global perspective.

Pudong New Area is a hub for China's biomedicine industry, housing over 3,800 biopharmaceutical companies and more than 300 service platforms. It accounts for 15 percent of the country's original innovative drugs and 10 percent of innovative medical devices, with an industry scale nearing 380 billion yuan ($54.20 billion).

Eight of the world's top 10 biopharmaceutical companies have established production bases and R&D centers in Pudong, attracting numerous international giants and innovative talent to explore the frontiers of life sciences together.

Source:"pdnews" WeChat account